28.73
3.75%
+1.03
Handel nachbörslich:
28.16
-0.57
-1.98%
BridgeBio Pharma Inc Aktie (BBIO) Neueste Nachrichten
Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down
Zacks Investment Research
Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow
Zacks Investment Research
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
Zacks Investment Research
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
GlobeNewswire Inc.
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
Zacks Investment Research
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
GlobeNewswire Inc.
Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug
Zacks Investment Research
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
GlobeNewswire Inc.
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
GlobeNewswire Inc.
BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
Benzinga
Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
GlobeNewswire Inc.
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
GlobeNewswire Inc.
BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines
GlobeNewswire Inc.
BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine
GlobeNewswire Inc.
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)
GlobeNewswire Inc.
2 Biotechs That Could Get Bought Out in 2024
The Motley Fool
The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023
MarketWatch
The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023
MarketWatch
The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023
MarketWatch
The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023
MarketWatch
BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia
GlobeNewswire Inc.
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
GlobeNewswire Inc.
BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
GlobeNewswire Inc.
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Kapitalisierung:
|
Volumen (24h):